Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Jazz Pharmaceuticals
Deal Size : $770.0 million
Deal Type : Licensing Agreement
Details : The agreement aims to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Jazz Pharmaceuticals
Deal Size : $770.0 million
Deal Type : Licensing Agreement
Lead Product(s) : AUT00206
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $50.1 million
Deal Type : Termination
Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme
Details : Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Autifony has regained full rights to its Kv3 programme.
Brand Name : AUT00206
Molecule Type : Small molecule
Upfront Cash : $29.5 million
August 26, 2020
Lead Product(s) : AUT00206
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $50.1 million
Deal Type : Termination
LOOKING FOR A SUPPLIER?
Reset All
